Edgewise’s R&D costs rise as drug candidates proceed through trials

BOULDER — Clinical-stage, pre-revenue pharmaceutical company Edgewise Therapeutics Inc. (Nasdaq: EWTX), which markets itself as a developer of “orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders,” posted higher year-over-year expenses and losses in the third quarter as its drug candidates move through the development pipeline. 

Research and development expenses were $23.8 million for the third quarter of 2023, up from $13.9 million in the third quarter of last year.

Net loss for the most recently period was $25.7 million, up from a loss of $17.4 million loss for the third quarter of 2022

EDG-5506, Edgewise’s flagship drug, is…